Novel second-generation Di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo

Journal of Medicinal Chemistry

Volumn 55, Issue 16, 2012, Pages 7230-7244

  Lovejoy, David B ^a   Sharp, Danae M ^a   Seebacher, Nicole ^a   Obeidy, Peyman ^a   Prichard, Thomas ^a   Stefani, Christian ^a   Basha, Maram T ^b   Sharpe, Philip C ^b   Jansson, Patric J ^a   Kalinowski, Danuta S ^a   Bernhardt, Paul V ^b   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHALDEHYDE ISONICOTINOYLHYDRAZONE; CISPLATIN; COPPER COMPLEX; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4 CYCLOHEXYL 4 METHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE 4 ETHYL 4 METHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE THIOSEMICARBAZONE DERIVATIVE; ETOPOSIDE; GEMCITABINE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COORDINATION COMPLEXES; COPPER; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; INJECTIONS, INTRAVENOUS; KETONES; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OXIDATION-REDUCTION; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOSEMICARBAZONES; TRANSFERRIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 84866887477     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300768u     Document Type: Article

References (59)

1. Kovacevic, Z.; Kalinowski, D. S.; Lovejoy, D. B.; Quach, P.; Wong, J.; Richardson, D. R. Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Curr. Drug Delivery 2010, 7, 194-207.
2. Yu, Y.; Wong, J.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond. Clin. Cancer Res. 2006, 12, 6876-6883.
3. Nyholm, S.; Mann, G. J.; Johansson, A. G.; Bergeron, R. J.; Graslund, A.; Thelander, L. Role of Ribonucleotide Reductase in Inhibition of Mammalian Cell Growth by Potent Iron Chelators. J. Biol. Chem. 1993, 268, 26200-26205.
4. Saletta, F.; Kovacevic, Z.; Richardson, D. R. Iron chelation: Deciphering Novel Molecular Targets for Cancer Therapy. The Tip of the Iceberg of a Web of Iron-Regulated Molecules. Future Med. Chem. 2011, 3, 1983-1986.
5. Yu, Y.; Gutierrez, E.; Kovacevic, Z.; Saletta, F.; Obeidy, P.; Rahmanto, Y. S.; Richardson, D. R. Iron Chelators for the Treatment of Cancer. Curr. Med. Chem. 2012, 19, 2689-2702.
6. Pahl, P. M.; Horwitz, L. D. Cell Permeable Iron Chelators as Potential Cancer Chemotherapeutic Agents. Cancer Invest. 2005, 23, 683-691.
7. Knox, J. J.; Hotte, S. J.; Kollmannsberger, C.; Winquist, E.; Fisher, B.; Eisenhauer, E. A. Phase II Study of Triapine in Patients with Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest. New Drugs 2007, 25, 471-477.
8. Ma, B.; Goh, B. C.; Tan, E. H.; Lam, K. C.; Soo, R.; Leong, S. S.; Wang, L. Z.; Mo, F.; Chan, A. T.; Zee, B.; Mok, T. A Multicenter Phase II Trial of 3-Aminopyridine-2-carboxaldehyde Thiosemicarba-zone (3-AP, Triapine) and Gemcitabine in Advanced Non-Small-Cell Lung Cancer with Pharmacokinetic Evaluation using Peripheral Blood Mononuclear Cells. Invest. New Drugs 2008, 26, 169-173.
9. Kalinowski, D. S.; Yu, Y.; Sharpe, P. C.; Islam, M.; Liao, Y. T.; Lovejoy, D. B.; Kumar, N.; Bernhardt, P. V.; Richardson, D. R. Design, Synthesis, and Characterization of Novel Iron Chelators: Structure-Activity Relationships of the 2-Benzoylpyridine Thiosemicarbazone Series and their 3-Nitrobenzoyl Analogues as Potent Antitumor Agents. J. Med. Chem. 2007, 50, 3716-3729.
10. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A Class of Iron Chelators with a Wide Spectrum of Potent Antitumor Activity that Overcomes Resistance to Chemotherapeutics. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 14901-14906.
11. Yu, Y.; Rahmanto, Y. S.; Richardson, D. R. Bp44mT: An Orally Active Iron Chelator of the Thiosemicarbazone Class with Potent Anti-Tumour Efficacy. Br. J. Pharmacol. 2012, 165, 148-166.
12. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel Di-2-pyridyl-Derived Iron Chelators with Marked and Selective Antitumor Activity: In Vitro and In Vivo Assessment. Blood 2004, 104, 1450-1458.
13. Quach, P.; Gutierrez, E.; Basha, M. T.; Kalinowski, D. S.; Sharpe, P. C.; Lovejoy, D. B.; Bernhardt, P. V.; Jansson, P. J.; Richardson, D. R. Methemoglobin Formation by 3-AP, Dp44mT and Other Anti-Cancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics that Prevent this Effect. Mol. Pharmacol. 2012, 82, 105-114.
14. Kovacevic, Z.; Chikhani, S.; Lovejoy, D. B.; Richardson, D. R. Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-Myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer. Mol. Pharmacol. 2011, 80, 598-609.
15. Rao, V. A.; Klein, S. R.; Agama, K. K.; Toyoda, E.; Adachi, N.; Pommier, Y.; Shacter, E. B. The Iron Chelator Dp44mT causes DNA Damage and Selective Inhibition of Topoisomerase IIalpha in Breast Cancer Cells. Cancer Res. 2009, 69, 948-957.
16. Tian, J.; Peehl, D. M.; Zheng, W.; Knox, S. J. Antitumor and Radiosensitization Activities of the Iron Chelator HDp44mT are Mediated by Effects on Intracellular Redox Status. Cancer Lett. 2010, 298, 231-237.
17. Jansson, P. J.; Hawkins, C. L.; Lovejoy, D. B.; Richardson, D. R The Iron Complex of Dp44mT is Redox-Active and Induces Hydroxyl Radical Formation: An EPR Study. J. Inorg. Biochem. 2010, 104, 1224-1228.
18. Lovejoy, D. B.; Jansson, P. J.; Brunk, U. T.; Wong, J.; Ponka, P.; Richardson, D. R Antitumor Activity of Metal-Chelating Compound Dp44mT is Mediated by Formation of a Redox-Active Copper Complex that Accumulates in Lysosomes. Cancer Res. 2011, 71, 5871 -5880.
19. Richardson, D. R; Sharpe, P. C; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl Thiosemi-carbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity. J. Med. Chem. 2006, 49, 6510-6521.
20. Kovacevic, Z.; Chikhani, S.; Lui, G. Y.; Sivagurunathan, S.; Richardson, D. R The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxid. Redox Signal. 2012, [online early access] PMID 22462691, published online May 8, 2012, DOI 10.1089/ars.2011.4273.
21. Le, N. T.; Richardson, D. R Iron Chelators with High Antiproliferative Activity Up-Regulate the Expression of a Growth Inhibitory and Metastasis Suppressor Gene: A Link Between Iron Metabolism and Proliferation. Blood 2004, 104, 2967-2975.
22. Liu, W.; Xing, F.; Iiizumi-Gairani, M.; Okuda, H; Watabe, M.; Pai, S. K.; Pandey, P. R; Hirota, S.; Kobayashi, A.; Mo, Y. Y.; Fukuda, K.; Li, Y.; Watabe, K. N-myc Downstream Regulated Gene 1 Modulates Wnt-Beta-Catenin Signalling and Pleiotropically Suppresses Metastasis. EMBO Mol. Med. 2012, 4, 93-108.
23. Gao, J.; Richardson, D. R The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents, IV: The Mechanisms Involved in Inhibiting Cell-Cycle Progression. Blood 2001, 98, 842-850.
24. Saletta, F.; Rahmanto, Y. S.; Siafakas, A R; Richardson, D. R Cellular Iron Depletion and the Mechanisms Involved in the Iron-Dependent-Regulation of the Growth Arrest and DNA Damage Family of Genes. J. Biol. Chem. 2011, 286, 35396-35406.
25. Lovejoy, D. B.; Richardson, D. R Novel "Hybrid" Iron Chelators Derived from Aroylhydrazones and Thiosemicarbazones Demonstrate Selective Antiproliferative Activity Against Tumor Cells. Blood 2002, 100, 666-676.
26. Scovill, J. P. A Facile Synthesis of Thiosemicarbazides and Thiosemicarbazones by the Transamination of 4-Methyl-4-phenyl-3- thiosemicarbazide. Phosphorus, Sulfur Silicon Relat. Elem. 1991, 60, 15-19.
27. Jansson, P. J.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R Novel Thiosemicarbazones of the ApT and DpT Series and their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of their Antitumor Activity. J. Med. Chem. 2010, 53, 5759-5769.
28. Richardson, D. R; Kalinowski, D. S.; Richardson, V.; Sharpe, P. C.; Lovejoy, D. B.; Islam, M.; Bernhardt, P. V. 2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity. J. Med. Chem. 2009, 52, 1459-1470.
29. Addison, A. W.; Rao, T. N; Reedijk, J.; Vanrijn, J.; Verschoor, G C. Synthesis, Structure, and Spectroscopic Properties of Copper(II) Compounds Containing Nitrogen Sulfur Donor Ligands-The Crystal and Molecular Structure of Aqua[1, 7-bis(N-methylbenzimida-zol-2'-yl)-2, 6-dithiaheptane]copper(II) perchlorate. Dalton Trans. 1984, 1349-1356.
30. Ali, M. A.; Mirza, A H.; Butcher, R J.; Bernhardt, P. V.; Karim, M. R Self-Assembling Dicopper(II) Complexes of Di-2-pyridyl Ketone Schiff Base Ligands Derived from S-Alkyldithiocarbazates. Polyhedron 2011, 30, 1478-1486.
31. Ali, M. A.; Mirza, A. H; Nazimuddin, M.; Ahmed, R; Gahan, L. R; Bernhardt, P. V. Synthesis and Characterization of Mono- and Bis-Ligand Zinc(II) and Cadmium(II) Complexes of the Di-2-pyridylketone Schiff Base of S-Benzyl Dithiocarbazate (Hdpksbz) and the X-ray Crystal Structures of the [Zn(dpksbz)(2)] and [Cd(dpksbz)NCS](2) Complexes. Polyhedron 2003, 22, 1471-1479.
32. Hathaway, B. J. A New Look at the Stereochemistry and Electronic-Properties of Complexes of the Copper(II) Ion. Struct. Bonding (Berlin, Ger.) 1984, 57, 55-118.
33. Hamid, M. H. S. A.; Ali, M. A.; Mirza, A. H.; Bernhardt, P. V.; Moubaraki, B.; Murray, K. S. Magnetic, Spectroscopic and X-ray Crystallographic Structural Studies on Copper(II) Complexes of Tridentate NNS Schiff Base Ligands formed from 2-Acetylpyrazine and S-Methyl- and S-Benzyldithiocarbazates. Inorg. Chim. Acta 2009, 362, 3648-3656.
34. Kalinowski, D. S.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Design, Synthesis, and Characterization of New Iron Chelators with Anti-Proliferative Activity: Structure-Activity Relationships of Novel Thiohydrazone Analogues. J. Med. Chem. 2007, 50, 6212-6225.
35. Richardson, D. R.; Tran, E. H.; Ponka, P. The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents. Blood 1995, 86, 4295-4306.
36. Stefani, C.; Punnia-Moorthy, G.; Lovejoy, D. B.; Jansson, P. J.; Kalinowski, D. S.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Halogenated 2′-Benzoylpyridine Thiosemicarbazone (XBpT) Chela-tors with Potent and Selective Antineoplastic Activity: Relationship to Intracellular Redox Activity. J. Med. Chem. 2011, 54, 6936-6948.
37. Yu, Y.; Suryo Rahmanto, Y.; Hawkins, C. L.; Richardson, D. R. The Potent and Novel Thiosemicarbazone Chelators Di-2-pyridylke-tone-4, 4-dimethyl-3-thiosemicarbazone and 2-Benzoylpyridine-4, 4-di-methyl-3- thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity. Mol. Pharmacol. 2011, 79, 921-931.
38. Nurtjahja-Tjendraputra, E.; Fu, D.; Phang, J. M.; Richardson, D. R. Iron Chelation Regulates Cyclin D1 Expression via the Proteasome: A Link to Iron Deficiency-Mediated Growth Suppression. Blood 2007, 109, 4045-4054.
39. Richardson, D. R.; Lovejoy, D. B. Dipyridyl thiosemicarbazone compounds and use in therapy. Provisional Patent Application number 2010905539, 2010.
40. D'Addario, G.; Fruh, M.; Reck, M.; Baumann, P.; Klepetko, W.; Felip, E. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2010, 21 (Suppl 5), v116-v119.
41. Simon, G. R.; Turrisi, A. Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd edition). Chest 2007, 132, 324S-339S.
42. Sorensen, M.; Pijls-Johannesma, M.; Felip, E. Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2010, 21 (Suppl 5), v120-v125.
43. Chou, T. C. Preclinical versus Clinical Drug Combination Studies. Leuk. Lymphoma 2008, 49, 2059-2080.
44. Chou, T. C. Drug Combination Studies and their Synergy Quantification using the Chou-Talalay Method. Cancer Res. 2010, 70, 440-446.
45. Chou, T. C.; Talalay, P. Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
46. Chou, T. C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol. Rev. 2006, 58, 621-681.
47. Suttie, A. W. Histopathology of the Spleen. Toxicol. Pathol. 2006, 34, 466-503.
48. Yu, Y.; Kalinowski, D. S.; Kovacevic, Z.; Siafakas, A. R.; Jansson, P. J.; Stefani, C.; Lovejoy, D. B.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Thiosemicarbazones from the Old to New: Iron Chelators that are More than just Ribonucleotide Reductase Inhibitors. J. Med. Chem. 2009, 52, 5271-5294.
49. Martinelli, R. A.; Hanson, G. R.; Thompson, J. S.; Holmquist, B.; Pilbrow, J. R.; Auld, D. S.; Vallee, B. L. Characterization of the Inhibitor Complexes of Cobalt Carboxypeptidase A by Electron Paramagnetic Resonance Spectroscopy. Biochemistry 1989, 28, 2251-2258.
50. Ghose, A K.; Crippen, G. M. Atomic Physicochemical Parameters for Three-Dimensional-Structure-Directed Quantitative Structure-Activity Relationships. 2. Modeling Dispersive and Hydro phobic Interactions. J. Chem. Inf. Comput. Sci. 1987, 27, 21-35.
51. Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R; Robins, R K. Atomic Physiochemical Parameters for 3-Dimensional-Structure Directed Quantitative Structure-Activity Relationships 4. Additional Parameters for Hydrophobic and Dispersive Interactions and their Application for an Automated Superposition of Certain Naturally-Occuring Nucleoside Antibiotics. J. Chem. Inf. Comput. Sci. 1987, 29, 163-172.
52. Broto, P.; Moreau, G; Vandycke, C. Molecular Structures: Perception, Autocorrelation Descriptor and SAR Studies. System of Atomic Contributions for the Calculation of the n-Octanol/Water Partition Coefficients. Eur. J. Med. Chem. Chim. Theor. 1984, 19, 71 -78.
53. Sheldrick, G A Short History of SHELX. Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112-122.
54. Farrugia, L. J. ORTEP-3 for Windows-A Version of ORTEP-III with a Graphical User Interface (GUI). J. Appl. Crystallogr. 1997, 30, 565.
55. Farrugia, L. J. WINGX-An Integrated System of Windows Programs for the Solution, Refinement and Analysis of Single Crystal X-Ray Diffraction Data. J. Appl. Crystallogr. 1999, 32, 837-838.
56. Rchardson, D. R; Baker, E. The Uptake of Iron and Transferrin by the Human Malignant Melanoma Cell. Biochim. Biophys. Acta 1990, 1053, 1-12.
57. Rchardson, D. R; Baker, E. Two Mechanisms of Iron Uptake from Transferrin by Melanoma Cells. The Effect of Desferoxamine and Ferric Ammonium Citrate. J. Biol. Chem. 1992, 267, 13972-13979.
58. Balsari, A.; Tortoreto, M.; Besusso, D.; Petrangolini, G; Sfondrini, L.; Maggi, R; Menard, S.; Pratesi, G Combination of a CpG-Oligodeoxynucleotide and a Topoisomerase I Inhibitor in the Therapy of Human Tumour Xenografts. Eur. J. Cancer 2004, 40, 1275-1281.
59. Sanceau, J.; Poupon, M. F.; Delattre, O.; Sastre-Garau, X.; Wietzerbin, J. Strong Inhibition of Ewing Tumor Xenograft Growth by Combination of Human Interferon-alpha or Interferon-beta with Ifosfamide. Oncogene 2002, 21, 7700-7709.